As HATs activity is dysregulated in cancer and causes overexpression of oncogenes in different tumours, especially leukaemia, BRPF1 has been exploited as a biological target for the development of potent and selective BRPF and BRPF1 inhibitors. Here, BRPF1 is linked to leukemia.